Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zymeworks (ZYME) Payables (2021 - 2025)

Zymeworks' Payables history spans 3 years, with the latest figure at $67.8 million for Q3 2023.

  • For Q3 2023, Payables rose 29.69% year-over-year to $67.8 million; the TTM value through Sep 2023 reached $67.8 million, up 29.69%, while the annual FY2022 figure was $87.5 million, 39.3% up from the prior year.
  • Payables for Q3 2023 was $67.8 million at Zymeworks, down from $69.9 million in the prior quarter.
  • Across five years, Payables topped out at $87.5 million in Q4 2022 and bottomed at $52.3 million in Q3 2022.
  • The 3-year median for Payables is $65.3 million (2021), against an average of $66.6 million.
  • The largest annual shift saw Payables skyrocketed 39.3% in 2022 before it grew 29.69% in 2023.
  • A 3-year view of Payables shows it stood at $62.8 million in 2021, then soared by 39.3% to $87.5 million in 2022, then decreased by 22.5% to $67.8 million in 2023.
  • Per Business Quant, the three most recent readings for ZYME's Payables are $67.8 million (Q3 2023), $69.9 million (Q2 2023), and $59.2 million (Q1 2023).